A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Sponsor
Centre Hospitalier Universitaire de Nice
Study ID
NCT06136403
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Epidermolysis Bullosa Simplex
  • Genodermatosis
  • Ichthyosis
  • Inflammatory Congenital Ichthyoses

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • deucravacitinib — DRUG
    treatment by deucravacitinib in two phases of challenge

Study Details

The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.

Key Dates

Start date
Mar 18, 2024
Status verified
Jul 2025
Primary completion
Sep 30, 2025
Completion
Oct 12, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: deucravacitinib treatment
    challenge-dechallenge -rechallenge design

Primary Outcome Measure

efficacy of deucravacitinib [ Time Frame: week 44 ]

Central Contacts

Related Studies